Astellas Pharma US Inc., of Northbrook, Ill., part of Astellas Pharma Inc., said it reached an agreement with the U.S. Department of Justice (DoJ) to resolve civil claims regarding the marketing of Mycamine (micafungin sodium) for injection and will pay $7.3 million to the settling parties. Read More
Cleveland Biolabs Inc., of Buffalo, New York, said it successfully evaluated CBL0102 (quinacrine), an orally administered small molecule, for maximum tolerated dose and dose-limiting toxicities in patients with advanced cancers during a phase I trial. Read More
Echelon Biosciences Inc., of Salt Lake City, said it acquired California Peptide Research Inc. to offer its line of biochemicals and research peptides, and to further drive innovations in the peptide research and development markets. Read More
Regado Biosciences Inc., of Basking Ridge, N.J., closed its underwritten public offering of 10 million shares at $6 each for gross proceeds of $60 million. Read More
HONG KONG – The CFDA gave the green light to Chongqing Zhifei Biological Products Co. Ltd. (SZ:300122) to launch its joint vaccine against group A and C meningococcus and haemophilus influenzae type B (AC-Hib). Zhifei's subsidiary, Beijing Zhifei Lvzhu Biopharmaceutical Co., developed the vaccine that aims to prevent infectious diseases such as meningitis, pneumonia, septicemia, cellulitis, arthritis and epiglottitis caused by group A and C meningococcus as well as type b haemophilus influenzae (Hib). Read More
LONDON – An all-share merger between Topotarget A/S and Bioalliance Pharma SA will create a Franco-Danish specialist in orphan drug oncology, with a product in registration, one in phase III and one in phase II. Read More
Wilson Therapeutics AB raised $40 million in a series B round to fund clinical development of WTX101 in Wilson's disease, a genetic disorder characterized by pathological accumulations of copper. Read More
An angina drug dating back to the 1970s until its use was curtailed due to toxicity is back in development, this time aimed at rare hereditary heart disease hypertrophic cardiomyopathy (HCM) in the hands of Heart Metabolics Ltd., which relaunched as an Irish firm and disclosed Thursday a $20 million series A round. Read More
Measles is officially targeted by the World Health Organization as an eradication disease. A highly effective vaccine against it does exist, and would in principle be enough to eradicate the virus. Read More
Iconic Therapeutics Inc., a small company developing a new therapy for wet age-related macular degeneration (AMD), raised $20 million in new equity financing and appointed MPM Capital partner William Greene CEO to lead the company through mid-stage testing and beyond. Read More
